Avid Bioservices Welcomes Rich McAvoy as New Chief Business Officer

Avid Bioservices, a prominent player in the contract development and manufacturing organization (CDMO) landscape, has recently announced the appointment of Rich McAvoy as its Chief Business Officer (CBO). This strategic move is aimed at propelling the company into its next growth chapter and optimizing client execution across its biopharmaceutical services.

McAvoy, recognized for his extensive background in business and finance, brings a wealth of expertise that spans across various domains including strategic investment management, operational finance, accounting, legal, compliance, and risk management. In his new role at Avid, he will oversee the company’s growth strategy with a strong emphasis on disciplined execution and scalable operations, ensuring an enhanced customer experience.

In a statement regarding McAvoy's appointment, Avid's CEO Kenneth Bilenberg expressed confidence in McAvoy's capabilities, stating, "Rich is a thoughtful, highly capable leader with a strong reputation for building disciplined organizations that support reliable delivery. His skills in aligning strategy with execution while maintaining rigorous compliance and risk management standards makes him an exceptional fit for Avid. We are excited to welcome him aboard as we broaden our partnerships and redefine what it means to be the most accessible CDMO partner."

McAvoy's hire comes during a crucial time in the biopharmaceutical sector, where many companies are reassessing their strategies to bolster supply chain resilience against ever-changing geopolitical climates and potential trade barriers. The COVID-19 pandemic underscored the importance of robust domestic manufacturing capabilities, prompting a reevaluation in sourcing and supply strategies, particularly within the context of U.S.-based manufacturing.

Rich McAvoy shared his enthusiasm about joining Avid during this pivotal time, highlighting the company's strong reputation for quality and delivery. He stated, "I am thrilled to be part of a talented team at Avid, especially at a moment when the company is focused on achieving its growth ambitions. My commitment will be to ensure disciplined execution — consistently delivering reliable results while improving the customer experience. By focusing on deliverables and execution, we will set ourselves apart from our competitors and establish Avid as a preferred partner in the biopharmaceutical landscape."

The addition of McAvoy to Avid’s leadership team is expected to further strengthen the company's existing capabilities and deepen its relationships with innovative biopharmaceutical companies. Avid Bioservices has built a solid foundation based on its commitment to quality and agility as it navigates the complexities of global regulatory frameworks to support both emerging biotech and established multinational pharmaceutical firms.

Based in Tustin, California, Avid specializes in mammalian cell culture manufacturing and boasts an impressive record of FDA compliance. The company’s track record includes over 600 batches manufactured, more than 275 commercial batches delivered globally, and a successful outcome in 10 critical pre-approval inspections across major regulatory agencies. With McAvoy's leadership, Avid is well-positioned to continue providing high-quality CGMP manufacturing for both clinical and commercial activities, helping its clients advance crucial projects effectively and efficiently.

In conclusion, McAvoy's appointment is anticipated to enhance Avid’s ability to respond to the evolving demands of the biopharmaceutical sector while ensuring consistent, high-quality service delivery, thereby reinforcing its status as a trusted partner in the industry.